Clinical Trial

Actualities in Procedural Sedation: Remimazolam

Active, Not Recruiting Phase 4

Record status

This record was last updated March 25, 2026 (before its estimated May 1, 2026 completion). Its status may not reflect the trial's current state.

Summary

Remimazolam is a new, ultra-short-acting benzodiazepine approved in Romania for procedural sedation. It shows significant clinical benefits compared to other sedatives like Propofol or Midazolam, especially in elderly or high-risk patients. Advantages include better hemodynamic stability, reduced respiratory depression, lower incidence of postoperative delirium, and rapid recovery without residual sedation. It is metabolized by liver esterases and is less affected by organ dysfunction. Clinical studies suggest that remimazolam may be a safer and more effective alternative in procedural and general anesthesia. The findings support the development of institutional protocols for its use, particularly in high-risk populations and endoscopic procedures.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2026-01-15.

Status change: Recruiting → Active, Not Recruiting 2026-03-23

Trial Details

NCT Number	NCT07362173
Lead Sponsor	Iuliu Hatieganu University of Medicine and Pharmacy Collaborators: Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor
Conditions	ASA Class III/IV Patients, COPD III/IV, Age 65 and Older, Multiple Organ Failure
Enrollment	200 participants
Start Date	2025-03-01
Primary Completion	2026-05-01 (estimated)
Study Completion	2026-05-01 (estimated)
Updated on ClinicalTrials.gov	2026-03-25